News

Liza C. Villaruz, MD, discusses what research in the EGFR-positive lung cancer space has recently caught the attention of experts.

In an interview with Targeted Oncology, Lisa B. Ercolano, MD, discussed the evolving treatment landscape for sarcomas and underscored the pivotal role of molecular profiling, while addressing the need for more efficacious systemic therapies.

The FDA breakthrough drug designation for epcoritamab in follicular lymphoma was supported by findings from the phase 1/2 EPCORE NHL-1 study.

An investigational new drug application for TCB008 has been cleared by the FDA. A phase 1B trial will now assess the agent in patients with relapsed/refractory acute myeloid leukemia.

Among patients with chronic lymphocytic leukemia who progressed after treatment, pirtobrutinib demonstrated a clearance of BTK C481 clones and the development of non-C481 clones.

Steady-state and chemotherapy-based mobilization both demonstrate feasibility in stem cell collection for patients with multiple myeloma undergoing autologous stem cell transplants, but challenges remain.

Mohamad Adham Salkeni, MD, FRCPC, discusses the mechanism of action of ivaltinostat and what rationalizes its use in combination with capecitabine for patients with metastatic pancreatic adenocarcinoma.

In an interview with Targeted Oncology, Jeff Stein, PhD, discussed the challenges and prospects of CD73-targeting agents.

In an interview with Targeted Oncology, Chris Haqq, MD, PhD, discussed the potential use of cancer vaccines in patients with KRAS-mutated pancreatic and colon cancer.

Domenech Asbun, MD, discusses first-, second-, and later lines of therapy for patients with gastrointestinal stromal tumor.

Neal Shore, MD, FACS, discussed the phase 3 EMBARK trial and what the FDA approval of enzalutamide means for the prostate cancer treatment landscape.

In addition to the approval of capivasertib and fulvestrant, the FDA has granted approval to the FoundationOne® CDx as a companion diagnostic to identify patients with advanced HR-positive, HER2-negative advanced breast cancer.

The rate of undetectable minimal residual disease at 10-4 in bone marrow was 77%, including a 71% rate among 14 patients with chronic lymphocytic leukemia refractory to prior Bruton tyrosine kinase inhibitors treated with venetoclax, umbralisib, and ublituximab.

VBI-1901 10µg plus GM-CSF had a disease control rate of 44% among 16 patients with recurrent glioblastoma in a phase 1/2a study.

Findings from the EPCORE CLL-1 trial were presented by Arnon Kater, MD, PhD, during the 2023 International Workshop on CLL, held October 6 to 9, 2023, in Boston, Massachusetts.

Nasir Chaudry, MD, discusses the significant advancements in the prostate cancer space in recent years.

AMG 193 had a promising safety profile and robust target engagement in a dose-escalating trial across tumor types.

Results from a phase 1/2a trial showed that plixorafenib had potential regarding safety and efficacy in BRAF-mutated solid tumors, especially in primary central nervous system tumors.

Along with improvements shown for the primary and secondary end points of the phase 3 MANIFEST-2 trial in JAK inhibitor-naive patients with myelofibrosis, pelabresib plus ruxolitinib did not display any new safety signals.

The combination of olaptesed pegol, bevacizumab, and radiotherapy showed an improvement in overall survival among patients with glioblastoma, according to findings from a phase 1/2 study.

In an interview with Targeted Oncology, Michael Wang, MD, discussed the rationale of the phase 3 study and how positive results from this trial may further shape the mantle cell lymphoma treatment landscape.

Adam J. Olszewski, MD, discusses the promising results of a phase 1b/2 study of mosunetuzumab for elderly/unfit patients with previously untreated diffuse large B-cell lymphoma.

RMC-6236 was safe and tolerable in patients with mutant solid tumors harboring KRAS G12X mutations across various cancer types.

The use of poly ADP ribose polymerase inhibitors in the treatment of metastatic castration-resistant prostate cancer were associated with an increased risk of hematological adverse events.

Positive findings from the MARIPOSA-2 study of amivantamab with chemotherapy with or without lazertinib in locally advanced or metastatic non–small cell lung cancer with EGFR mutations support the submission of a supplemental biologics license application to the FDA.

Ariel Lopez-Chavez, MD, discusses available frontline options for patients with small cell lung cancer, then moves into second-line treatments.

In this article, John M. Burke, MD, discusses the high prices of prescription drugs and the new law that allows the government to negotiate drug prices with manufacturers.

Clark DuMontier, MD, discusses the main takeaways from his presentation on treatment intensity and frailty in newly diagnosed patients with multiple myeloma given at the 20th International Myeloma Society Annual Meeting.

At the recent European Society for Medical Oncology Congress 2023, a number of trials evaluated antibody-drug conjugates in non–small cell lung cancer.